MedTrace Logo

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

NCT02608112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2020-02-11

No results posted yet for this study

Summary

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

Methotrexate

Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.

DRUG

Tocilizumab

Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-07-26
Completion
2018-07-26

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608112 on ClinicalTrials.gov